skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine (Code C48393)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine

Definition: A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.

Label: HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine

NCI Thesaurus Code: C48393 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1708275  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine
Survivin Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 433196
PDQ Open Trial Search ID 433196 (check for NCI PDQ open clinical trial info)
UMLS CUI C1708275

Other Properties:
     Name Value (qualifiers indented underneath)
code C48393
Legacy_Concept_Name HLA-A1_A2_B35-Restricted_Survivin_Peptides_Montanide_ISA-51_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48393

Mainbox Bottom